Abstract
There is an increasing focus on personalized treatment approaches in advanced and metastatic urothelial carcinoma (mUC). Recent advancements include biomarker-driven therapy selection, novel antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and targeted therapies. Managing treatment-related toxicities remains crucial, requiring interprofessional collaboration to monitor and mitigate adverse events. At JADPRO Live 2024, presenters discussed these considerations for advanced practitioners.
